Cargando…
Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial
BACKGROUND: Preventative measures have recently been taken to reduce the incidence of Alzheimer’s disease worldwide. We previously showed that Met-Lys-Pro (MKP), a casein-derived angiotensin-converting enzyme inhibitory peptide with the potential to cross the blood–brain barrier, attenuated cognitiv...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266326/ https://www.ncbi.nlm.nih.gov/pubmed/32546992 http://dx.doi.org/10.2147/CIA.S253116 |
_version_ | 1783541286586810368 |
---|---|
author | Yuda, Naoki Tanaka, Miyuki Yamauchi, Koji Abe, Fumiaki Kakiuchi, Izumi Kiyosawa, Kyoko Miyasaka, Mitsunaga Sakane, Naoki Nakamura, Masahiko |
author_facet | Yuda, Naoki Tanaka, Miyuki Yamauchi, Koji Abe, Fumiaki Kakiuchi, Izumi Kiyosawa, Kyoko Miyasaka, Mitsunaga Sakane, Naoki Nakamura, Masahiko |
author_sort | Yuda, Naoki |
collection | PubMed |
description | BACKGROUND: Preventative measures have recently been taken to reduce the incidence of Alzheimer’s disease worldwide. We previously showed that Met-Lys-Pro (MKP), a casein-derived angiotensin-converting enzyme inhibitory peptide with the potential to cross the blood–brain barrier, attenuated cognitive decline in a mouse model of Alzheimer’s disease. However, the effect of MKP on cognitive function improvement in humans remains unknown. This exploratory study sought to investigate whether MKP intake could improve cognitive function in adults without dementia. METHODS: A total of 268 community-dwelling adults without dementia participated in this 24-week randomized controlled trial. Participants were randomly allocated to the MKP (n = 134) or placebo (n = 134) group. The MKP group received four tablets daily, each containing 50 μg MKP, while the placebo group received four dextrin tablets containing no detectable MKP for 24 weeks. Scores on the Japanese version of the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog) were used as the primary outcome to compare cognitive function between the MKP and placebo groups. The study products were also evaluated for safety. RESULTS: The intention-to-treat analysis showed that there was no significant difference between the groups in terms of the ADAS-cog total score. Orientation, as measured by the respective ADAS-cog subscale, was significantly improved compared to placebo at 24 weeks post-MKP administration (P = 0.022). No serious adverse events due to MKP intake were observed. CONCLUSION: To the best of our knowledge, this is the first study to report the effects of MKP on human cognition. These preliminary results suggested the safety of daily MKP intake and its potential to improve orientation in adults without dementia. Further clinical studies are needed to confirm the present findings and the benefits of MKP on cognitive function. |
format | Online Article Text |
id | pubmed-7266326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-72663262020-06-15 Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial Yuda, Naoki Tanaka, Miyuki Yamauchi, Koji Abe, Fumiaki Kakiuchi, Izumi Kiyosawa, Kyoko Miyasaka, Mitsunaga Sakane, Naoki Nakamura, Masahiko Clin Interv Aging Original Research BACKGROUND: Preventative measures have recently been taken to reduce the incidence of Alzheimer’s disease worldwide. We previously showed that Met-Lys-Pro (MKP), a casein-derived angiotensin-converting enzyme inhibitory peptide with the potential to cross the blood–brain barrier, attenuated cognitive decline in a mouse model of Alzheimer’s disease. However, the effect of MKP on cognitive function improvement in humans remains unknown. This exploratory study sought to investigate whether MKP intake could improve cognitive function in adults without dementia. METHODS: A total of 268 community-dwelling adults without dementia participated in this 24-week randomized controlled trial. Participants were randomly allocated to the MKP (n = 134) or placebo (n = 134) group. The MKP group received four tablets daily, each containing 50 μg MKP, while the placebo group received four dextrin tablets containing no detectable MKP for 24 weeks. Scores on the Japanese version of the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog) were used as the primary outcome to compare cognitive function between the MKP and placebo groups. The study products were also evaluated for safety. RESULTS: The intention-to-treat analysis showed that there was no significant difference between the groups in terms of the ADAS-cog total score. Orientation, as measured by the respective ADAS-cog subscale, was significantly improved compared to placebo at 24 weeks post-MKP administration (P = 0.022). No serious adverse events due to MKP intake were observed. CONCLUSION: To the best of our knowledge, this is the first study to report the effects of MKP on human cognition. These preliminary results suggested the safety of daily MKP intake and its potential to improve orientation in adults without dementia. Further clinical studies are needed to confirm the present findings and the benefits of MKP on cognitive function. Dove 2020-05-27 /pmc/articles/PMC7266326/ /pubmed/32546992 http://dx.doi.org/10.2147/CIA.S253116 Text en © 2020 Yuda et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Yuda, Naoki Tanaka, Miyuki Yamauchi, Koji Abe, Fumiaki Kakiuchi, Izumi Kiyosawa, Kyoko Miyasaka, Mitsunaga Sakane, Naoki Nakamura, Masahiko Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial |
title | Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial |
title_full | Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial |
title_fullStr | Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial |
title_full_unstemmed | Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial |
title_short | Effect of the Casein-Derived Peptide Met-Lys-Pro on Cognitive Function in Community-Dwelling Adults Without Dementia: A Randomized, Double-Blind, Placebo-Controlled Trial |
title_sort | effect of the casein-derived peptide met-lys-pro on cognitive function in community-dwelling adults without dementia: a randomized, double-blind, placebo-controlled trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266326/ https://www.ncbi.nlm.nih.gov/pubmed/32546992 http://dx.doi.org/10.2147/CIA.S253116 |
work_keys_str_mv | AT yudanaoki effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial AT tanakamiyuki effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial AT yamauchikoji effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial AT abefumiaki effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial AT kakiuchiizumi effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial AT kiyosawakyoko effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial AT miyasakamitsunaga effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial AT sakanenaoki effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial AT nakamuramasahiko effectofthecaseinderivedpeptidemetlysprooncognitivefunctionincommunitydwellingadultswithoutdementiaarandomizeddoubleblindplacebocontrolledtrial |